{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:15:55Z","timestamp":1770894955639,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ark Diagnostics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methotrexate, an antifolate therapy, is used for the treatment of cancers, autoimmune disease, and transplant patients and needs to be carefully monitored for toxicity. Plasma measurement of methotrexate concentrations is problematic as a result of analytical interference of its metabolites. Immunoassays are widely used for monitoring therapeutic drug levels of methotrexate; however, chromatographic assays, LC-MS\/MS most particularly, are preferentially used since they are less prone to metabolite interference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Analytical performance was evaluated in a second-generation methotrexate immunoassay (ARK, Inc.) by testing precision, accuracy, linearity, interference, and method comparison with LC-MS\/MS. Cross-reactivity of the immunoassay with 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA), 7-OH methotrexate, and folic acid was also measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Findings indicate that the within-run %CV ranged from 2.6% to 4.4% across control materials. The assay was linear across an analytical measuring range of 0.03 to 1.3\u2005\u03bcM. The lower limit of the measuring interval and the lower limit of detection were established at 0.03\u2005\u00b5M and 0.0067\u2005\u03bcM, respectively. Notable interference from DAMPA was observed above 1\u2005\u00b5M, whereas 7-OH methotrexate and folic acid showed no interference up to 5\u2005\u00b5M and 1000\u2005\u00b5M, respectively. Correlation studies showed an average 3% bias in DAMPA-free samples (R2 = 0.9935) and a significant bias and poorer correlation (R2 = 0.3241) in samples containing DAMPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The assay performed well based on the validation experiments and is suitable for most clinical applications involving methotrexate. However, the significant interference with DAMPA highlights the necessity for careful assay selection and interpretation of glucarpidase-treated patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfaf166","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:02:03Z","timestamp":1759406523000},"page":"73-82","source":"Crossref","is-referenced-by-count":0,"title":["Analytical Validation of a Second-Generation Methotrexate Immunoassay"],"prefix":"10.1093","volume":"11","author":[{"given":"Rebecca","family":"Wilson","sequence":"first","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Cincinnati Children\u2019s Hospital , Cincinnati, OH ,","place":["United States"]},{"name":"Department of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati , Cincinnati, OH ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Garrett","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schmeling","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Kuest","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6449-0243","authenticated-orcid":false,"given":"Andrew N","family":"Hoofnagle","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA ,","place":["United States"]},{"name":"Departmant of Medicine, University of Washington , Seattle, WA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"2026021205170769800_jfaf166-B1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","article-title":"The clinical pharmacology of methotrexate: new applications of an old drug","volume":"41","author":"Bleyer","year":"1978","journal-title":"Cancer"},{"key":"2026021205170769800_jfaf166-B2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: an old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"2026021205170769800_jfaf166-B3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","article-title":"Methotrexate mechanism in treatment of rheumatoid arthritis","volume":"86","author":"Friedman","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2026021205170769800_jfaf166-B4","first-page":"980301","article-title":"Methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"2014","author":"Nassar","year":"2014","journal-title":"J Transplant"},{"key":"2026021205170769800_jfaf166-B5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate\u2013how does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"2026021205170769800_jfaf166-B6","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.xphs.2018.01.004","article-title":"Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma","volume":"107","author":"Mei","year":"2018","journal-title":"J Pharm Sci"},{"key":"2026021205170769800_jfaf166-B7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0022-3565(24)39150-5","article-title":"Pharmacokintics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid","volume":"294","author":"Widemann","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2026021205170769800_jfaf166-B8","doi-asserted-by":"crossref","first-page":"1015200","DOI":"10.3389\/fonc.2022.1015200","article-title":"Therapeutic drug monitoring for cytotoxic anticancer drugs: principles and evidence-based practices","volume":"12","author":"Smita","year":"2022","journal-title":"Front Oncol"},{"key":"2026021205170769800_jfaf166-B9","first-page":"e29518","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed","year":"2022","journal-title":"Cureus"},{"key":"2026021205170769800_jfaf166-B10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1634\/theoncologist.12-11-1299","article-title":"Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy","volume":"12","author":"Schwartz","year":"2007","journal-title":"Oncologist"},{"key":"2026021205170769800_jfaf166-B11","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/pbc.25395","article-title":"Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients","volume":"62","author":"Scott","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2026021205170769800_jfaf166-B12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/phar.1360","article-title":"Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","author":"Widemann","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2026021205170769800_jfaf166-B13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1373\/clinchem.2011.175067","article-title":"Liquid chromatography-tandem mass spectrometry work flow for parallel quantification of methotrexate and other immunosuppressants","volume":"58","author":"Nair","year":"2012","journal-title":"Clin Chem"},{"key":"2026021205170769800_jfaf166-B14","doi-asserted-by":"crossref","first-page":"e4159","DOI":"10.1002\/bmc.4159","article-title":"Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: a brief review","volume":"32","author":"Silva","year":"2018","journal-title":"Biomed Chromatogr"},{"key":"2026021205170769800_jfaf166-B15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/clinchem\/42.1.39","article-title":"Evaluation of clinical assays for measuring high-dose methotrexate in plasma","volume":"42","author":"Albertioni","year":"1996","journal-title":"Clin Chem"},{"key":"2026021205170769800_jfaf166-B16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jchromb.2004.11.037","article-title":"Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays","volume":"817","author":"Fotoohi","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026021205170769800_jfaf166-B17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ajcp\/aqw088","article-title":"Evaluation of a methotrexate chemiluminescent microparticle immunoassay: comparison to fluorescence polarization immunoassay and liquid chromatography-tandem mass spectrometry","volume":"146","author":"Bouquie","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"2026021205170769800_jfaf166-B18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/FTD.0000000000000053","article-title":"Unexpected overestimation of methotrexate plasma concentrations: analysis of a single center pediatric population","volume":"36","author":"Guerriero","year":"2014","journal-title":"Ther Drug Monit"},{"key":"2026021205170769800_jfaf166-B19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/FTD.0000000000000205","article-title":"Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs","volume":"37","author":"Christians","year":"2015","journal-title":"Ther Drug Monit"},{"key":"2026021205170769800_jfaf166-B20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-60761-459-3_34","article-title":"Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for monitoring methotrexate in the setting of carboxypeptidase-G2 therapy","volume":"603","author":"Kumar","year":"2010","journal-title":"Methods Mol Biol"},{"key":"2026021205170769800_jfaf166-B21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1055\/s-0042-1760668","article-title":"A rapid method for determination of serum methotrexate using ultra-high-performance liquid chromatography-tandem mass spectrometry and its application in therapeutic drug monitoring","volume":"15","author":"Tripathy","year":"2023","journal-title":"J Lab Physicians"},{"key":"2026021205170769800_jfaf166-B22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-4939-8823-5_10","article-title":"Quantification of methotrexate in human serum and plasma by liquid chromatography tandem mass spectrometry","volume":"1872","author":"Winston-McPherson","year":"2019","journal-title":"Methods Mol Biol"},{"key":"2026021205170769800_jfaf166-B23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpha.2019.06.001","article-title":"Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples","volume":"9","author":"Karami","year":"2019","journal-title":"J Pharm Anal"},{"key":"2026021205170769800_jfaf166-B24","author":"Valdez"},{"key":"2026021205170769800_jfaf166-B25","year":"2017"},{"key":"2026021205170769800_jfaf166-B26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"key":"2026021205170769800_jfaf166-B27","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1200\/JOP.19.00566","article-title":"Decreasing cost and decreasing length of stay after implementation of updated high-dose methotrexate discharge criteria","volume":"16","author":"Binder","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2026021205170769800_jfaf166-B28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1078155220983407","article-title":"Comparison of four immunoassays to an HPLC method for the therapeutic drug monitoring of methotrexate: influence of the hydroxylated metabolite levels and impact on clinical threshold","volume":"28","author":"Descoeur","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"2026021205170769800_jfaf166-B29","doi-asserted-by":"crossref","first-page":"1237178","DOI":"10.3389\/fonc.2023.1237178","article-title":"Case report: Serum methotrexate monitoring by immunoassay: confusion by by-product, confusion by antidote","volume":"13","author":"Sharma","year":"2023","journal-title":"Front Oncol"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/11\/1\/73\/65000525\/jfaf166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/11\/1\/73\/65000525\/jfaf166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:17:18Z","timestamp":1770891438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/11\/1\/73\/8304783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2026,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfaf166","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,28]]}}}